EXEL
Exelixis
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About EXEL
Exelixis, Inc.
A biotech company that develops novel small molecule therapies to treat cancer
Biological Technology
Invalid Date
04/11/2000
NASDAQ Stock Exchange
1147
12-31
Common stock
1851 Harbor Bay Parkway, Alameda, California 94502
--
Exelixis, Inc., is a biotechnology company engaged in the development of small molecule therapies for cancer. The Company was incorporated in Delaware as Exelixis Pharmaceuticals, Inc., in November 1994 and changed to Exelixis, Inc., in February 2000. The company's resources, R & D, and production focus on COMETRIQ (cabozantinib capsules, the company's wholly-owned multi-target receptor tyrosine kinase inhibitor). The company aims to develop COMETRIQ into a major licensed oncology product, and believes that the approval of COMETRIQ's treatment of deteriorating, metastatic MTC provides an opportunity to achieve this goal and establish a commercial position.
Company Financials
EPS
EXEL has released its 2024 Q4 earnings. EPS was reported at 0.55, versus the expected 0.49, beating expectations. The chart below visualizes how EXEL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EXEL has released its 2024 Q4 earnings report, with revenue of 566.76M, reflecting a YoY change of 18.16%, and net profit of 139.86M, showing a YoY change of 63.55%. The Sankey diagram below clearly presents EXEL’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
